Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.04 (-10.90%)
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
Rein Therapeutics cash
Cash and short-term investments held at the end of each period.
Rein Therapeutics's cash was $43.63M at Jun 30, 2026. For fiscal 2025 it was $3.22M, down 75.0% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $50.75M in fiscal 2017.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.22M | -75.0% |
| FY2024 | Dec 31, 2024 | $12.87M | -25.8% |
| FY2023 | Dec 31, 2023 | $17.34M | -18.4% |
| FY2022 | Dec 31, 2022 | $21.24M | -53.8% |
| FY2021 | Dec 31, 2021 | $45.93M | +232.7% |
| FY2020 | Dec 31, 2020 | $13.81M | -24.5% |
| FY2019 | Dec 31, 2019 | $18.28M | -11.7% |
| FY2018 | Dec 31, 2018 | $20.70M | -59.2% |
| FY2017 | Dec 31, 2017 | $50.75M | +144.0% |
| FY2016 | Dec 31, 2016 | $20.80M | +452.1% |
| FY2015 | Dec 31, 2015 | $3.77M | -39.3% |
| FY2014 | Dec 31, 2014 | $6.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.63M | +662.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.45M | -40.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.22M | -75.0% |
| Q3 FY2025 | Sep 30, 2025 | $4.05M | -77.1% |
| Q2 FY2025 | Jun 30, 2025 | $5.72M | -73.9% |
| Q1 FY2025 | Mar 31, 2025 | $7.43M | -38.3% |
| Q4 FY2024 | Dec 31, 2024 | $12.87M | -25.8% |
| Q3 FY2024 | Sep 30, 2024 | $17.65M | +46.3% |
| Q2 FY2024 | Jun 30, 2024 | $21.92M | +60.4% |
| Q1 FY2024 | Mar 31, 2024 | $12.04M | -28.0% |
| Q4 FY2023 | Dec 31, 2023 | $17.34M | -18.4% |
| Q3 FY2023 | Sep 30, 2023 | $12.07M | -52.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.67M | -57.8% |
| Q1 FY2023 | Mar 31, 2023 | $16.72M | -56.1% |
| Q4 FY2022 | Dec 31, 2022 | $21.24M | -53.8% |
| Q3 FY2022 | Sep 30, 2022 | $25.48M | -51.2% |
| Q2 FY2022 | Jun 30, 2022 | $32.38M | -45.6% |
| Q1 FY2022 | Mar 31, 2022 | $38.08M | -39.9% |
| Q4 FY2021 | Dec 31, 2021 | $45.93M | +232.7% |
| Q3 FY2021 | Sep 30, 2021 | $52.23M | +269.9% |
| Q2 FY2021 | Jun 30, 2021 | $59.48M | +215.0% |
| Q1 FY2021 | Mar 31, 2021 | $63.35M | +399.0% |
| Q4 FY2020 | Dec 31, 2020 | $13.81M | -24.5% |
| Q3 FY2020 | Sep 30, 2020 | $14.12M | -42.5% |
| Q2 FY2020 | Jun 30, 2020 | $18.88M | -40.1% |
| Q1 FY2020 | Mar 31, 2020 | $12.70M | -4.3% |
| Q4 FY2019 | Dec 31, 2019 | $18.28M | -11.7% |
| Q3 FY2019 | Sep 30, 2019 | $24.56M | -12.1% |
| Q2 FY2019 | Jun 30, 2019 | $31.52M | -11.9% |
| Q1 FY2019 | Mar 31, 2019 | $13.27M | -69.3% |
| Q4 FY2018 | Dec 31, 2018 | $20.70M | -59.2% |
| Q3 FY2018 | Sep 30, 2018 | $27.95M | -50.9% |
| Q2 FY2018 | Jun 30, 2018 | $35.79M | +215.5% |
| Q1 FY2018 | Mar 31, 2018 | $43.29M | +433.3% |
| Q4 FY2017 | Dec 31, 2017 | $50.75M | +144.0% |
| Q3 FY2017 | Sep 30, 2017 | $56.87M | +1162.5% |
| Q2 FY2017 | Jun 30, 2017 | $11.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $20.80M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.50M | – |
See a number that looks wrong?